Martin A. Cheever, Wei Chen, Mary L. Disis, Masazumi Takahashi, David Peace,
... 98195Search for more papers by this authorMARY L. DISIS, MARY L. DISIS Division of Medical Oncology Mail Stop RM-17 ... 98195Search for more papers by this authorMARY L. DISIS, MARY L. DISIS Division of Medical Oncology Mail Stop RM-17 ... Peace, D. J., J. W. Smith, M. L. Disis, W. Chen & M. A. Cheever. T cells specific ... 40 Chen, W., S. G. You, M. L. Disis & M. A. Cheever. 1993. Evaluation of the joining ...
Tópico(s): Cytomegalovirus and herpesvirus research
1993 - Wiley | Annals of the New York Academy of Sciences
Giuseppe Curigliano, Gianluca Spitaleri, Elisabetta Pietri, María Rescigno, Filippo de Braud, Anna Cardillo, Elisabetta Munzone, Andrea Rocca, Giuseppina Bonizzi, Vincent Brichard, Laura Orlando, Aron Goldhirsch,
... protein, elicited a delayed type hypersensitivity (DTH) [11.Disis M.L. Shiota F.M. Cheever M.A. ... summarizes all clinical trials with HER2/neu peptides. Disis [12.Disis M.L. Grabstein K.H. Sleath P.R. ... Knutson K.L. Schiffman K. Cheever M.A. Disis M.L. Immunization of cancer patients with a ... breast or lung cancerFour HER2 peptides plus GMCSFNR25%Disis, 200429 with NED after surgery for HER2-overexpressing ... which needs a long-term follow-up [19.Disis M.L. Schiffman K. Guthrie K. et al. ...
Tópico(s): Cancer Immunotherapy and Biomarkers
2005 - Elsevier BV | Annals of Oncology
Sasha E. Stanton, Mary L. Disis,
... interests disclosureSE Stanton was supported by KL2TR000421. ML Disis was supported by the Athena Distinguished Professor of ... U01CA141539 and DOD W81XWH-11-1-0760. ML Disis holds a Komen Leadership Award and has several ... 9), 756–765 (2006).Crossref, Medline, Google Scholar20 Disis ML, Gad E, Herendeen DR et al. A ... interests disclosureSE Stanton was supported by KL2TR000421. ML Disis was supported by the Athena Distinguished Professor of ... U01CA141539 and DOD W81XWH-11-1-0760. ML Disis holds a Komen Leadership Award and has several ...
Tópico(s): vaccines and immunoinformatics approaches
2015 - Future Medicine | Immunotherapy
Martin A. Cheever, Mary L. Disis, Helga Bernhard, Julie R. Gralow, Susan L. Hand, Eric S. Huseby, Hui Qin, Masazumi Takahashi, Wei Chen,
... Search for more papers by this authorMary L. Disis, Mary L. Disis Department of Medicine. Division of Medical Oncology. Box ... Search for more papers by this authorMary L. Disis, Mary L. Disis Department of Medicine. Division of Medical Oncology. Box ...
Tópico(s): Immunotherapy and Immune Responses
1995 - Wiley | Immunological Reviews
Olesya Chornoguz, Alexei Gapeev, Michael C. O’Neill, Suzanne Ostrand‐Rosenberg,
... S.K. Ksander B.R. Knutson K.L. Disis M.L. Ostrand-Rosenberg S. Tumor cells transduced ... S.K. Ksander B.R. Knutson K.L. Disis M.L. Ostrand-Rosenberg S. Tumor cells transduced ... Knutson K.L. Gooley T.A. Schiffman K. Disis M.L. Immunization of cancer patients with HER- ... S.K. Ksander B.R. Knutson K.L. Disis M.L. Ostrand-Rosenberg S. Tumor cells transduced ...
Tópico(s): T-cell and B-cell Immunology
2012 - Elsevier BV | Molecular & Cellular Proteomics
Barry S. Taylor, Manoj K. Pal, Jianjun Yu, Bharathi Laxman, Shanker Kalyana‐Sundaram, Rong Zhao, Anjana Menon, John T. Wei, Alexey I. Nesvizhskii, Debashis Ghosh, Gilbert S. Omenn, David M. Lubman, Arul M. Chinnaiyan, Arun Sreekumar,
... Storer B.E. Vessella R. Lange P.H. Disis M.L. Antibody immunity to prostate cancer associated ... Storer B.E. Vessella R. Lange P.H. Disis M.L. Antibody immunity to prostate cancer associated ...
Tópico(s): Monoclonal and Polyclonal Antibodies Research
2007 - Elsevier BV | Molecular & Cellular Proteomics
... et al., Cancer Res 60:1777–1788, 2000; Disis et al., J Clin Oncol 15(11):3363– ... LaBaer, J Proteome Res 4:1123–1133, 2005; Disis et al., J Clin Oncol 15(11):3363– ...
Tópico(s): Advanced Proteomics Techniques and Applications
2014 - Springer Science+Business Media | Methods in molecular biology
... 188.2.373 CASPubMedWeb of Science®Google Scholar Disis, M.L. & Cheever, M.A. (1996) Oncogenic proteins ... 96)80079-3 CASPubMedWeb of Science®Google Scholar Disis, M.L., Grabstein, K.H., Sleath, P.R., ...
Tópico(s): T-cell and B-cell Immunology
2001 - Wiley | British Journal of Haematology
Colby S. Shemesh, Joy Hsu, Iraj Hosseini, Ben‐Quan Shen, Anand Rotte, Patrick Twomey, Sandhya Girish, Benjamin Wu,
... 19Romero P. Banchereau J. Bhardwaj N. Cockett M. Disis M.L. Dranoff G. Gilboa E. Hammond S. ... 1721Crossref Scopus (1) Google Scholar, 29Knutson K.L. Disis M.L. Tumor antigen-specific T helper cells ...
Tópico(s): Cancer Immunotherapy and Biomarkers
2020 - Elsevier BV | Molecular Therapy
Kirsten Bibbins‐Domingo, Annette Flanagin, Caroline Sietmann, Robert O. Bonow, Ann Marie Návar, Kanade Shinkai, Mya L. Roberson, John Z. Ayanian, Ninez A. Ponce, Sharon K. Inouye, Raegan W. Durant, Melissa A. Simon, Frederick P. Rivara, Mónica B. Vela, S. Andrew Josephson, Ashley Rawls, Mary L. Disis, Narjust Florez, Neil M. Bressler, Adrienne W. Scott, Jay F. Piccirillo, Nosayaba Osazuwa‐Peters, Dimitri Christakis, Andrea F. Duncan, Döst Öngür, Kara Bagot, Melina R. Kibbe, Leah M. Backhus, Preeti Malani,
... Bressler, MD; Dimitri Christakis, MD, MPH; Mary L. Disis, MD; S. Andrew Josephson, MD; Melina R. Kibbe, ...
Tópico(s): Health Systems, Economic Evaluations, Quality of Life
2024 - American Medical Association | JAMA
Péter M. Szabó, Saumya Pant, Scott Ely, Keyur Desai, Esperanza Anguiano, Lisu Wang, Robin Edwards, George Green, Nancy Zhang,
... S. Dennis L. D'Amico L. White A. Disis M.L. Geller M.A. Odunsi K. Beechem ... S. Dennis L. D'Amico L. White A. Disis M.L. Geller M.A. Odunsi K. Beechem ...
Tópico(s): Immunotherapy and Immune Responses
2021 - Elsevier BV | Journal of Molecular Diagnostics
Howard Bauchner, Frederick P. Rivara, Robert O. Bonow, Neil M. Bressler, Mary L. Disis, Stephan Heckers, S. Andrew Josephson, Melina R. Kibbe, Jay F. Piccirillo, Rita F. Redberg, John S. Rhee, June K. Robinson,
... O. Bonow, Neil M. Bressler, Mary L. (Nora) Disis, Stephan Heckers, S. Andrew Josephson, Melina R. Kibbe, ... O. Bonow, Neil M. Bressler, Mary L. (Nora) Disis, Stephan Heckers, S. Andrew Josephson, Melina R. Kibbe, ...
Tópico(s): Posttraumatic Stress Disorder Research
2017 - American Medical Association | JAMA Facial Plastic Surgery
R. Scafè, R. Pellegrini, A. Soluri, L. Montani, Angelo Tatì, M.N. Cinti, G. Cusanno, G. Trotta, R. Pani, F. Garibaldi,
... volume). An overview of discrete scintillation imager simulator (DISIS) computer code is reported. Major outcomes of this ... the improved expression of SLD, which consolidates the DISIS performances, and 2) a tool for local SLD- ...
Tópico(s): Atomic and Subatomic Physics Research
2004 - Institute of Electrical and Electronics Engineers | IEEE Transactions on Nuclear Science
Stéphanie Gaillard, Robert L. Coleman,
... cancer, they are frequently durable (Table 1) [8.Disis M.L. Taylor M.H. Kelly K. et ... with response in this or prior studies [8.Disis M.L. Taylor M.H. Kelly K. et ...
Tópico(s): Ovarian cancer diagnosis and treatment
2019 - Elsevier BV | Annals of Oncology
Mary L. Disis, Kathy Schiffman,
... U.S.A. Address correspondence to Mary L. Disis, Department of Oncology, University of Washington, Box 356527, ...
Tópico(s): vaccines and immunoinformatics approaches
2001 - Lippincott Williams & Wilkins | Journal of Immunotherapy
Eckart Meese, Nicole Comtesse,
... specific library probes. Hum Genet 80: 235–246. Disis ML, Cheever MA. 1996. Oncogenic proteins as tumor antigens. Curr Opin Immunol 8: 637–642. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen ...
Tópico(s): Cancer Genomics and Diagnostics
2001 - Wiley | Genes Chromosomes and Cancer
Ruben F. Gittes, David L. McCullough,
... L, STORER B, VESSELLA R, LANGE P and DISIS M (2018) ANTIBODY IMMUNITY TO PROSTATE CANCER ASSOCIATED ...
Tópico(s): Urologic and reproductive health conditions
1974 - Lippincott Williams & Wilkins | The Journal of Urology
Mary L. Disis, Thomas L. McDonald, John L. Colombo, Roger H. Kobayashi, Carol R. Angle, Susan Murray,
Circulating immune complexes (CIC) have been found to be elevated in individuals with cystic fibrosis (CF). Previous investigators, using a variety of assays, have reported high levels of CIC in as many as 86% of these patients. Our study followed the progress of 25 patients with CF over a period of 10 months to determine which, if any, clinical parameters correlated with the occurrence and/or concentration of CIC. Immune complex determinations were performed using a coprecipitation method with equine ...
Tópico(s): Pneumonia and Respiratory Infections
1986 - Springer Nature | Pediatric Research
Keith L. Knutson, Mary L. Disis,
Abstract Despite aggressive multimodal treatment approaches, the prognosis for patients with diffuse gliomas remains disappointing. Glioma cells often extensively infiltrate in the surrounding brain parenchyma, a phenomenon that helps them to escape surgical removal, radiation exposure and chemotherapy. Moreover, conventional therapy is often associated with considerable local and systemic side effects. Therefore, the development of novel therapeutic approaches is essential to improve the outcome ...
Tópico(s): Glioma Diagnosis and Treatment
2009 - Wiley | Brain Pathology
Mary L. Disis, Kyong Hwa Park,
It has long been assumed that the immune system plays a role in tumor eradication, however, scant clinical evidence exists to support that hypothesis. In recent years, as the immune system and its specific effector cells are better defined, convincing data supporting immune surveillance is emerging. Several studies have shown that an "immune signature" in the tumor microenvironment is associated with a superior outcome in a variety of cancer types. Moreover, studies have suggested that T cells found ...
Tópico(s): Monoclonal and Polyclonal Antibodies Research
2009 - Korean Cancer Association | Cancer Research and Treatment
Sebastian Tuve, Ying Liu, Khajornsak Tragoolpua, Jeffrey Jacobs, Roma Yumul, Zong-Yi Li, Robert Strauss, K E Hellström, Mary L. Disis, Steve R. Roffler, André Lieber,
The efficacy of cancer immunotherapy is limited because of central and peripheral immune tolerance towards tumor-antigens. We propose a novel approach based on the fact that the immune system has not evolved tolerance towards adenoviruses (Ads) and that Ads have not evolved efficient mechanisms for immune-escape. The host-response to intratumoral Ad-vector injection in mice that were immunologically tolerant to neu-positive syngeneic mammary-cancer (MMC) was investigated. Intratumoral injection with ...
Tópico(s): CAR-T cell therapy research
2009 - Elsevier BV | Vaccine
Lupe G. Salazar, Vivian Goodell, Megan M. O’Meara, Keith L. Knutson, Yushe Dang, C dela Rosa, Katherine A. Guthrie, Mary L. Disis,
3010 Background: Our initial vaccine studies showed that optimally treated breast cancer patients can be immunized against HER2 during active immunization. The majority of patients developed T-cell immunity to HER2 peptides and protein and also epitope spreading (ES). The goal of this study was to determine if patients previously immunized with a HER2 vaccine had persistent immunity years after active immunization and to assess their clinical outcome in terms of overall survival (OS). Methods: Subjects ...
Tópico(s): Cancer Immunotherapy and Biomarkers
2009 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Leisha A. Emens, Justin M. Asquith, James M. Leatherman, Barry Kobrin, S. Petrik, Marina Laiko, J A Levi, Maithili M. Daphtary, Barbara Biedrzycki, Antonio C. Wolff, Vered Stearns, Mary L. Disis, Xiaobu Ye, Steven Piantadosi, John H. Fetting, Nancy E. Davidson, Elizabeth M. Jaffee,
Granulocyte-macrophage colony-stimulating factor (GM-CSF) -secreting tumor vaccines have demonstrated bioactivity but may be limited by disease burdens and immune tolerance. We tested the hypothesis that cyclophosphamide (CY) and doxorubicin (DOX) can enhance vaccine-induced immunity in patients with breast cancer.We conducted a 3 x 3 factorial (response surface) dose-ranging study of CY, DOX, and an HER2-positive, allogeneic, GM-CSF-secreting tumor vaccine in 28 patients with metastatic breast cancer. ...
Tópico(s): Immune Cell Function and Interaction
2009 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Hideaki Tahara, Marimo Sato, Magdalena Thurin, Ena Wang, Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, Peter P. Lee, Samir N. Khleif, Jon M. Wigginton, Stefan Ambs, Yasunori Akutsu, Damien Chaussabel, Yuichiro� Doki, Oleg Eremin, Wolf H. Fridman, Yoshihiko Hirohashi, Kohzoh Imai, James W. Jacobson, Masahisa Jinushi, Akira Kanamoto, Mohammed Kashani‐Sabet, Kazunori Kato, Yutaka Kawakami, John M. Kirkwood, Thomas O. Kleen, Paul Lehmann, Lance A. Liotta, Michael T. Lotze, Michele Maio, Anatoli Malyguine, Giuseppe Masucci, Hisahiro Matsubara, Shawmarie Mayrand-Chung, Kiminori Nakamura, Hiroyoshi Nishikawa, A. Karolina Palucka, Emanuel F. Petricoin, Zoltán Pós, Antoni Ribas, Licia Rivoltini, Noriyuki Sato, Hiroshi Shiku, Craig L. Slingluff, Howard Streicher, David F. Stroncek, Hiroya Takeuchi, Minoru Toyota, Hisashi Wada, Xifeng Wu, Julia Wulfkuhle, Tomonori Yaguchi, Benjamin Zeskind, Yingdong Zhao, Mai-Britt Zocca, Francesco M. Marincola,
Supported by the Office of International Affairs, National Cancer Institute (NCI), the "US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. The effort will culminate on October 28th 2009 in the "iSBTc-FDA- ...
Tópico(s): Immune cells in cancer
2009 - BioMed Central | Journal of Translational Medicine
Mary L. Disis, Danelle R. Wallace, Theodore A. Gooley, Yushe Dang, Meredith Slota, Hailing Lu, Andrew L. Coveler, Jennifer S. Childs, Doreen M. Higgins, Patricia A. Fintak, Corazon dela Rosa, Kathleen Tietje, John S. Link, James Waisman, Lupe G. Salazar,
The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity of combination therapy consisting of concurrent trastuzumab and human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients with HER2/neu-overexpressing metastatic breast cancer.Twenty-two patients with stage IV HER2/neu-positive breast cancer receiving trastuzumab therapy were vaccinated with an HER2/neu T-helper peptide-based vaccine. Toxicity was graded according to National ...
Tópico(s): Immunotherapy and Immune Responses
2009 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Mary L. Disis, Helga Bernhard, Elizabeth M. Jaffee,
The stimulation of a tumour-specific T-cell response has several theoretical advantages over other forms of cancer treatment. First, T cells can home in to antigen-expressing tumour deposits no matter where they are located in the body—even in deep tissue beds. Additionally, T cells can continue to proliferate in response to immunogenic proteins expressed in cancer until all the tumour cells are eradicated. Finally, immunological memory can be generated, allowing for eradication of antigen-bearing ...
Tópico(s): Cancer Research and Treatments
2009 - Elsevier BV | The Lancet
Fatimah Jaafar, Elda Righi, Victoria Lindstrom, Christine Linton, Mahrokh Nohadani, Susan Van Noorden, Tyler Lloyd, Joshua Poznansky, Gordon Stamp, Roberto Dina, Dulcie V. Coleman, Mark C. Poznansky,
... Daniel B Gordon A Myers L Lackner A Disis ML Knutson KL Chen L Zou W Specific ...
Tópico(s): interferon and immune responses
2009 - Elsevier BV | American Journal Of Pathology
Zongyi Li, Ying Liu, Sebastian Tuve, Xun Ye, Xiaolong Fan, Liang Min, Qinghua Feng, Nancy Kiviat, Hans‐Peter Kiem, Mary Leonora Disis, André Lieber,
Current approaches for treatment of late-stage breast cancer rarely result in a long-term cure. In part this is due to tumor stroma that prevents access of systemically or intratumorally applied therapeutics. We propose a stem cell gene therapy approach for controlled tumor stroma degradation that uses the pathophysiologic process of recruitment of inflammatory cells into the tumor. This approach involves genetic modification of hematopoietic stem cells (HSCs) and their subsequent transplantation ...
Tópico(s): Neonatal Respiratory Health Research
2009 - Elsevier BV | Blood
Kathy Schiffman, Kristine Rinn, Mary L. Disis,
Tópico(s): T-cell and B-cell Immunology
2002 - Springer Science+Business Media | Breast Cancer Research and Treatment
Mary L. Disis, Kristine Rinn, Keith L. Knutson, Donna Davis, Dania Caron, Corazon dela Rosa, Kathy Schiffman,
Abstract Dendritic cells (DCs) are potent antigen-presenting cells and have shown promise to function as “natural” vaccine adjuvants. Currently, most cancer vaccine trials using DCs generate autologous DCs ex vivo for each patient. Systemic treatment with Flt3 ligand (FL) results in a marked increase of DCs in tissues such as spleen and lymph nodes in mice and in the peripheral blood and skin of humans. In light of these observations, we questioned whether FL could be used systemically as a vaccine ...
Tópico(s): T-cell and B-cell Immunology
2002 - Elsevier BV | Blood